INM InMed Pharmaceuticals Inc. stock chart & analysis

Conviction 4HealthcareScan · Wed, Nov 4, 2026

InMed Pharmaceuticals Inc. (INM) closed at $1.80 (+7.14%) on Nov 4, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 81, RS Rating 94, -22.8% from its 52-week high, +69.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.

INM$1.80+7.14%

ResistanceSupportVol 14Insider buy

Loading chart…

Why INM moved

From the StockSetups movers recaps that covered INM, newest first. A recap states what was known that day.

Jul 22, 2026Premarket+45.3%
The data points to a merger catalyst. INMed filed a Form 425 (a merger-related communication) on July 20, and a separate 8-K noting an agreement on July 10, with an S-4 merger registration filed July 2.
Premarket Stock Movers — July 22, 2026: Why LABT, INLF, INM, CHAI & ZCMD Are Surging →

InMed Pharmaceuticals Inc.Pharmaceutical Preparationswww.inmedpharma.com ↗

Price1.80

Change+7.14%

Gap+1.19%

Rel volume—

Avg volume70.31K

Avg $ vol109.64K

SMA 201.46

SMA 501.40

SMA 2001.21

Price vs 50+28.93%

Price vs 200+48.59%

MA stackbullish

50/200 cross—

Supertrendup · 1.40

RSI (14)81

MACD hist0.04

MACD cross—

Stoch %K / %D96 / 88

ADX (14)42

+DI / −DI31 / 8

RSI divergence—

MACD divergenceBearish

ATR %5.84%

ADR %6.27%

52w high2.33

52w low0.5750

From 52w high-22.75%

Above 52w low+213.04%

New 52w highNo

SqueezeOff

Bollinger width41.24%

%B1.06

Donchian pos96.08%

Donchian high1.82

Donchian low1.31

AVWAP (52w high)1.79

vs AVWAP high+0.47%

AVWAP (52w low)1.65

vs AVWAP low+9.20%

OBV trendUp

Chaikin MF (20)0.20

Today vs 20d—

Avg vol (14d)86.87K

Avg vol (20d)70.31K

Avg $ vol (20d)109.64K

Market cap—

RS Rating94 / 99

RS 3m (vs SPY)+26.11%

RS 6m (vs SPY)+143.31%

RS line new highYes

Trend template8/8

Technical rank98.7

1 week+12.56%

1 month+35.34%

3 months+25.87%

6 months+147.80%

1 year-2.70%

YTD+69.81%

P/E-0.74

P/B-7.72

P/S—

P/FCF-1.07

EPS-3.12

Div yield—

ROE—

ROA—

Debt/Eq-0.02

Current0.65

EV/EBITDA—

Gross margin—

Net margin—

Rev growth7.50%

EPS growth-53.89%

Price target—

Target upside—

Analyst rating—

Institutional49.10%

Ent. value8.19M

Revenue—

Net income-2.33M

Gross profit—

Free cash flow-8.65M

IndustryPharmaceutical Preparations

ExchangeNasdaq

Shares out3.31M

Employees13

ListedTue, Nov 10, 2020

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction4 / 100

Pattern quality—

Tech rank98.7 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.59

Support1.28

Days since event—

Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

INM technical analysis

Trend

INM is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 28.9% above the 50-day ($1.40) and 48.6% above the 200-day ($1.21). ADX(14) at 42 points to a strong, established trend. It meets 8 of 8 trend-template criteria.

Momentum

RSI(14) is 81, in overbought territory. The MACD histogram is positive. A bearish MACD divergence is in place. Its RS Rating of 94 puts its weighted 12-month performance ahead of about 94% of the US market, and its RS line is at a new high.

Volume and volatility

It trades about $109,644 a day on average. ATR(14) is $0.1050, 5.8% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.20) shows accumulation.

Key levels

The chart pattern's support is $1.28 and its resistance $1.59. The 52-week range is $0.5750 to $2.33; price is 22.8% below the high and 213.0% above the low. The VWAP anchored at the 52-week high is $1.79, below price.

Performance

INM returned +12.6% (1 week), +35.3% (1 month), +25.9% (3 months), +147.8% (6 months), -2.7% (1 year), +69.8% (year to date).

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.

Pharmaceutical Preparations · Listed 2020 · 13 employees

Insider activity

SEC Form 4 transactions in INM · open-market 10 buys

Insider	Side	Shares	Value	Traded	Filed
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-23	Buy	4	$5	2026-10-23	2026-10-27
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-15	Buy	984	$1K	2026-10-15	2026-10-15
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-14	Buy	8.02K	$11K	2026-10-14	2026-10-15
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-13	Buy	564	$750	2026-10-13	2026-10-15
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-05	Buy	18.18K	$24K	2026-10-05	2026-10-05
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-02	Buy	8.31K	$11K	2026-10-02	2026-10-05
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-10-01	Buy	16.43K	$22K	2026-10-01	2026-10-05
ADAR1 Capital Management, LLC 10% owner · Common Shares · 2026-07-15	Buy	1K	$2K	2026-07-15	2026-07-17
Vivo Opportunity, LLC 10% owner · Common Shares · 2026-07-16	Buy	19	$29	2026-07-16	2026-07-16
Vivo Opportunity, LLC 10% owner · Common Shares · 2026-07-16	Buy	2	$3	2026-07-16	2026-07-16

SEC filings

EDGAR filings in INM · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.